Articles in Category: More News

Meet us at Bio-Europe Spring in Barcelona!

News from Friday, 01 March 2013.

We are looking forward to meeting you at the highly effective partnering conference "Bio-Europe Spring 2013", held in Barcelona in the time between March 11-13th 2013!

We will be delighted to meet with you in a one-to-one partnering meeting or informally at one of the receptions!
And there´s always the opportunity of chatting over a real Austrian cup of coffee and some Mozart-chocolate at the Austrian booth "LISA"! Sounds good?

See you in Barcelona!

Third European Patent for Biomarker Submitted!

News from Tuesday, 01 January 2013.

After submitting european patents for lysosomal storage deseases in 2011 (Gaucher) and 2012 (NPC) in December last year we submitted another patent for a marker for MLD!

All three markers have remarkably high sensitivity as well as specificity.
pharm-analyt is continuously investigating in biomarkers, predominantly Small Molecules in plasma.

pharm-analyt at Bio-Europe ´12 in Hamburg

News from Thursday, 01 November 2012.

We´re looking forward to meeting many old acquaintances again and sure to meet many new people as we participate once more in the Bio-Europe conference in Hamburg!

See you soon!

pharm-analyt presenting at LISA Life Science Lecture on Oct. 11th

News from Monday, 01 October 2012.

"A short bioanalytical feasibility is the most efficient way preparing optimally for first in-vivo studies" was the message of the presentation given by Christian Kikuta and Martin van Dam.
The afternoon was dedicated to the subject "Preparing for 1st In-Man / Preclinical Strategies", organized by LISA, the Austrian life science cluster organization.

In the early phase of developing a compound obviously the bioanalytical behavior is vastly unknown. Yet the upcoming TOX or Dose Range Finding Study want to be planned optimally, in the light of the large lumps of budget absorbed by them.

A bioanalytical feasibility is a 2-4 day ballpark investigation of the bioanalytical behavior in plasma (or respective matrices). Output are rudimentary data on: stability in plasma, detectability, linearity, rough limits of detection and selectivity.

In combination with a pilot pre-clinical study administering the compound to 2-3 rodents, even important first information on bioavailibility can be gained, such as first-pass-effect, metabolism or protein binding.

The benefits are obvious:
- Reduction of Risk and disclosing latent "bad news"
- Estimation of effort and cost for upcoming in vivo trials
- Knowing scope of data to expect of pre-clinics
- Improved position towards VCs and authorities

In context with in-vivo pilot study:
- Pre-conclustions on administrative route
- Impression of bioavailibility / metabolism
- Orientation for dose range

Summary: Cut Risk and Cost with Preliminary Data.

pharm-analyt´s head of QA/QM Timo Kretzschmar assigned to lecture at Campus Tulln

News from Saturday, 01 September 2012.

Starting with September 2012 pharm-analyt´s head of QA/QM, Timo Kretzschmar, will be lecturing “QM Systems in Biotech and Pharmacy” at Campus Tulln (FH Wiener Neustadt).

Dr. Kretzschmar is a remarkable expert in quality management in context of pharma and Life Science. He has an intriguing mix of knowledge, experience and excitement for his subjects GLP and GMP.
His record of lecturing on academic level goes back to 2004.